Dudediligence.

Inhibrx Biosciences, Inc

INBXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$100,000Dec ’24$1.3MJun ’25$0.00Sep ’25$0.00Dec ’25$0.00Jun ’26
Net income, by quarter
−$43.9MSep ’24−$47.9MDec ’24−$43.3MMar ’25−$28.7MJun ’25−$35.3MSep ’25−$32.8MDec ’25−$33.4MMar ’26−$36.6MJun ’26
Fiscal years, by the month each ended
LineDec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on file$1.8M$200,000$1.3M
Operating incomenone on file−$219.2M−$331.4M−$135.0M
Net incomenone on file−$241.4M$1.69B−$140.1M
Operating cash flownone on file−$193.3M−$194.4M−$129.8M
Free cash flownone on file−$197.9M−$197.0M−$129.8M
Cash$273.9M$277.9M$152.6M$124.2M
Debtnone on file$207.0M$0.00$100.6M
Shares outstandingnone on file47.4M14.5M14.6M